Paclitaxel delivery using carrier made from curcumin derivative: Synergism between carrier and the loaded drug for effective cancer treatment

Journal of Pharmaceutical Sciences

Volumn 101, Issue 10, 2012, Pages 3779-3786

  Amornwachirabodee, Kittima ^a   Chiablaem, Khajeelak ^b   Wacharasindhu, Sumrit ^a   Lirdprapamongkol, Kriengsak ^b   Svasti, Jisnuson ^b,c   Vchirawongkwin, Viwat ^a   Wanichwecharungruang, Supason P ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b Krung Thep Maha Nakhon   (Thailand)

^c Mahidol University ^*  (Thailand)

Author keywords

Cancer; Curcumin; Delivery; Paclitaxel; Synergism

Indexed keywords

CURCUMIN; DRUG CARRIER; MICROSPHERE; PACLITAXEL; PALMITIC ACID; TRIACYLGLYCEROL LIPASE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG SYNTHESIS; ENDOCYTOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MORTALITY;

EID: 84865350113     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23263     Document Type: Article

References (27)

1. Sarkar FH, Li Y. 2009. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Canc Treat Rev 35:597-607.
2. Singh S, Aggarwal BB. 1995. Erratum: Activation of transcription factor NF-κb is suppressed by curcumin (diferuloylmethane) J Biol Chem 270:30235.
3. Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV. 2007. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 296:85-95.
4. Chearwae W, Wu CP, Chu HY, Lee TR, Ambudkar SV, Limtrakul P. 2006. Curcuminoids purified from turmeric powder modulate the function of human multidrug resistance protein 1 (ABCC1). Cancer Chemother Pharmacol 57:376-388.
5. Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D, Anto RJ. 2005. Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-κB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem 280:6301-6308.
6. Bava SV, Sreekanth CN, Thulasidasan AKT, Anto NP, Cheriyan VT, Puliyappadamba VT, Menon SG, Ravichandran SD, Anto RJ. 2011. Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int J Biochem Cell Biol 43:331-341.
7. Shishodia S, Amin HM, Lai R, Aggarwal BB. 2005. Curcumin (diferuloylmethane) inhibits constitutive NF-κB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70:700-713.
8. Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE, Price JE. 2005. Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Can Res 11:7490-7498.
9. Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. 2005. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor κB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 104:879-890.
10. Sreekanth CN, Bava SV, Sreekumar E, Anto RJ. 2011. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene 30:3139-3152.
11. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, Lin JK. 1997. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal 15:1867-1876.
12. Tonnesen HH, Karlsen J, van Henegouwen GB. 1986. Studies on curcumin and curcuminoids VIII. Photochemical stability of curcumin. Z Lebensmitt Unters Forsch 183:116-122.
13. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. 2007. Bioavailability of curcumin: Problems and promises. Mol Pharm 4:807-818.
14. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP. 2001. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res 7:1894-1900.
15. Suwannateep N, Banlunara W, Wanichwecharungruang SP, Chiablaem K, Lirdprapamongkol K, Svasti J. 2011. Mucoadhesive curcumin nanospheres: Biological activity, adhesion to stomach mucosa and release of curcumin into the circulation. J Control Release 151:176-182.
16. Dong X, Mattingly CA, Tseng M, Cho M, Adams VR, Mumper RJ. 2009. Development of new lipid-based paclitaxel nanoparticles using sequential simplex optimization. Eur J Pharm Biopharm 72:9-17.
17. Mugabe C, Hadaschik BA, Kainthan RK, Brooks DE, So AI, Gleave ME, Burt HM. 2009. Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy. BJU Int 103:978-986.
18. Israelachvili JN, Mitchell DJ, Ninham BW. 1976. Theory of self-assembly of hydrocarbon amphiphiles into micelles and bilayers. J Chem Soc Faraday Trans 2 72:1525-1568.
19. Israelachvili JN, Mitchell DJ, Ninham BW. 1977. Theory of self-assembly of lipid bilayers and vesicles. Biochim Biophys Acta 470:185-201.
20. Vchirawongkwin S, Vchirawongkwin V. 2011. Evaluation of molecular radial distribution function and solvent-excluded volume with the numerical integration of the union of spheres. Comp Theor Chem 974:26-30.
21. Laohathai K, Bhamarapravati N. 1985. Culturing of human hepatocellular carcinoma. A simple and reproducible method. Am J Pathol 118:203-208.
22. Kanintronkul Y, Worayuthakarn R, Thasana N, Winayanuwattikun P, Pattanapanyasat K, Surarit R, Ruchirawat S, Svasti J. 2011. Overcoming multidrug resistance in human lung cancer with novel benzo[a]quinolizin-4-ones. Anticancer Res 31:921-927.
23. Letchford K, Liggins R, Burt H. 2008. Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: Theoretical and experimental data and correlations. J Pharmacol Sci 97:1179-1190.
24. Bennewitz MF, Lobo TL, Nkansah MK, Ulas G, Brudvig GW, Shapiro EM. 2011. Biocompatible and pH-sensitive PLGA encapsulated MnO nanocrystals for molecular and cellular MRI. ACS Nano 5:3438-3446.
25. Schliehe C, Redaelli C, Engelhardt S, Fehlings M, Mueller M, Van Rooijen N, Thiry M, Hildner K, Weller H, Groettrup M. 2011. CD8- dendritic cells and macrophages cross-present poly(D, L-lactate-co-glycolate) acid microsphere-encapsulated antigen in vivo. J Immunol 187:2112-2121.
26. Fernandez EM, Chang J, Fontaine J, Bialecki E, Rodriguez F, Werkmeister E, Krieger V, Ehret C, Heurtault B, Fournel S, Frisch B, Betbeder D, Faveeuw C, Trottein F. 2012. Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles. Int J Pharm 423:45-54.
27. Wichitnithad W, Nimmannit U, Callery PS, Rojsitthisak P. 2011. Effects of different carboxylic ester spacers on chemical stability, release characteristics, and anticancer activity of mono-PEGylated curcumin conjugates. J Pharm Sci 100:5206-5218.